NewEdge Advisors LLC Has $974,000 Stake in Chemed Corporation $CHE

Key Points

• NewEdge Advisors increased its Chemed stake by 4,167.3% in the second quarter, ending with 2,091 shares worth approximately $974,000. Institutional investors collectively own 95.85% of Chemed.
• Chemed exceeded quarterly earnings expectations, reporting EPS of $6.06 versus the $5.60 consensus and revenue of $673.25 million, up 8.8% year over year. The company also raised its quarterly dividend to $0.70 per share.
• Chemed shares opened at $496.77, while analysts maintained a consensus “Hold” rating with an average price target of $530.75. Company insiders have sold 7,190 shares worth $3.81 million over the past 90 days.

NewEdge Advisors LLC lifted its position in Chemed Corporation (NYSE:CHE - Free Report) by 4,167.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,091 shares of the company's stock after buying an additional 2,042 shares during the quarter. NewEdge Advisors LLC's holdings in Chemed were worth $974,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Monetary Solutions Ltd acquired a new stake in shares of Chemed in the 4th quarter valued at $25,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Chemed in the second quarter worth about $34,000. Versant Capital Management Inc boosted its stake in shares of Chemed by 7,500.0% during the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company's stock worth $35,000 after acquiring an additional 75 shares in the last quarter. Keating Financial Advisory Services Inc. bought a new stake in shares of Chemed during the 2nd quarter worth about $36,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of Chemed by 65.3% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company's stock worth $38,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Insider Activity

In related news, EVP Spencer Lee sold 1,000 shares of the company's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the transaction, the executive vice president directly owned 13,912 shares in the company, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin McNamara sold 2,000 shares of the firm's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $501.40, for a total value of $1,002,800.00. Following the completion of the transaction, the chief executive officer directly owned 68,418 shares of the company's stock, valued at approximately $34,304,785.20. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 7,190 shares of company stock worth $3,806,260. Company insiders own 3.33% of the company's stock.

Chemed Stock Down 0.6%

CHE opened at $496.77 on Wednesday. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $557.00. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $6.49 billion, a price-to-earnings ratio of 24.95, a P/E/G ratio of 2.01 and a beta of 0.51. The business has a 50 day moving average of $523.25 and a 200-day moving average of $456.97.

Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. The business had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. Chemed's revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, sell-side analysts anticipate that Chemed Corporation will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 17th. This is a boost from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is 14.06%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CHE. Wall Street Zen downgraded Chemed from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Weiss Ratings raised Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. Oppenheimer increased their price target on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Bank of America reissued a "neutral" rating on shares of Chemed in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their price objective on shares of Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Chemed presently has a consensus rating of "Hold" and an average price target of $530.75.

About Chemed

Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients' homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.

Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.